Second Sight Medical Products (EYES) Trading 4.3% Higher

Second Sight Medical Products Inc (NASDAQ:EYES)’s share price traded up 4.3% during mid-day trading on Tuesday . The company traded as high as $0.75 and last traded at $0.72. 819,275 shares were traded during mid-day trading, an increase of 162% from the average session volume of 312,120 shares. The stock had previously closed at $0.69.

A number of equities analysts recently issued reports on the company. Zacks Investment Research lowered Second Sight Medical Products from a “buy” rating to a “hold” rating in a research note on Tuesday, January 8th. ValuEngine upgraded Second Sight Medical Products from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, HC Wainwright set a $5.00 target price on Second Sight Medical Products and gave the stock a “buy” rating in a research note on Thursday, November 8th.

Get Second Sight Medical Products alerts:

The stock has a market capitalization of $55.12 million, a price-to-earnings ratio of -1.25 and a beta of 2.26.

In related news, Director Gregg Williams purchased 3,275,100 shares of the business’s stock in a transaction on Wednesday, December 12th. The shares were bought at an average cost of $0.92 per share, with a total value of $3,013,092.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold a total of 15,417 shares of company stock worth $16,389 over the last ninety days. 48.30% of the stock is owned by insiders.

An institutional investor recently bought a new position in Second Sight Medical Products stock. B. Riley Wealth Management Inc. purchased a new position in shares of Second Sight Medical Products Inc (NASDAQ:EYES) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 53,500 shares of the medical device company’s stock, valued at approximately $102,000. B. Riley Wealth Management Inc. owned 0.07% of Second Sight Medical Products as of its most recent filing with the Securities and Exchange Commission. 9.63% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.tickerreport.com/banking-finance/4152277/second-sight-medical-products-eyes-trading-4-3-higher.html.

Second Sight Medical Products Company Profile (NASDAQ:EYES)

Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. It focuses on developing new technologies to treat the population of sight-impaired individuals. The company is developing the Orion Visual Cortical Prosthesis, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms of cancer and trauma.

Recommended Story: What is the Bid-Ask Spread?